NOTV Inotiv, Inc.
USHealthcareAs of 2026-06-10 16:00
Why NOTV matters now
Inotiv, Inc. (NOTV) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.08 with +121.94% on the session and $2.8M in market capitalization; recent performance reads 1-month -69.39% and YTD -85.79%.
The latest financial table shown here is Q2 2026, with revenue of $117.7M, net income of $-32.5M, and EPS of $-0.94. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3901.6%.
The latest indexable market news headline is "Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes DAVIS EUGENE I filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
46.38
DCF Value
$-92.08
FCF Yield
-3901.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
14.7%
Operating Margin
-8.9%
Net Margin
-17.1%
ROE
-74.7%
ROA
-12.4%
ROIC
-6.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $117.7M | $-32.5M | $-0.94 |
| Q1 2026 | $120.9M | $-28.4M | $-0.83 |
| Q4 2025 | $138.1M | $-8.6M | $-0.25 |
| FY 2025 | $513.0M | $-68.6M | $-2.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.67
Target (Median)
$6.00
Target Range
$3.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
3.77
Inotiv, Inc. is a specialized life sciences company that delivers preclinical research and development solutions to the biopharmaceutical, chemical, and medical technology sectors. Additionally, it manufactures and supplies advanced analytical instrumentation for drug development and contract research organizations (CROs). The company's operations are divided into two primary divisions: Contract Research Services (CRS): This segment provides a comprehensive suite of services, including early-stage pharmacological screening, non-clinical safety assessments, formulation development support, regulatory compliance, and quality control testing. Its offerings also encompass analytical method development and validation; in-depth drug metabolism, bioanalysis, and pharmacokinetics (DMPK) studies to precisely quantify drug and metabolite concentrations in complex biological matrices; specialized in vivo sampling for continuous biological monitoring; stability testing for both preclinical and clinical formulations; non-clinical toxicology and pathology evaluations; and secure, climate-controlled archiving for client data and biological samples. Research Products: This division focuses on the design, manufacturing, and commercialization of specialized in vivo sampling systems, complete with accessories, consumables, training, and qualification support. It also offers physiological monitoring tools and a range of analytical instrumentation, particularly liquid chromatography and electrochemistry platforms and their associated accessories. A notable product line includes the Culex family of automated in vivo sampling and dosing instrumentation. Inotiv maintains a significant global footprint, serving clients across the United States, broader North America, the Pacific Rim, Europe, and other international markets. The company recently partnered with BioVaxys for preclinical toxicity studies related to its Covid-T Immunodiagnostic program. Founded in 1974, the company was initially known as Bioanalytical Systems, Inc. before rebranding as Inotiv, Inc. in March 2021. Its headquarters are located in West Lafayette, Indiana.